Table 3.
Concordance in risk stratification between the BCT score and Oncotype DX RS in patients aged ≤50 years according to clinical risk.
|
All (n = 514) |
Lymph node-negative (n = 410) |
Lymph node-positive (n = 104) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Oncotype DX RS (TAILORx cut-off according to clinical risk) |
Oncotype DX RS (TAILORx cut-off according to clinical risk) |
Oncotype DX RS (TAILORx cut-off according to clinical risk) |
||||||||
| n (%) |
Non-chemobenefit (0–15 for clinical high risk or 0–20 for clinical low risk) |
Chemobenefit (≥21 for clinical low risk or ≥16 for clinical high risk) |
Total |
Non-chemobenefit (0–15 for clinical high risk or 0–20 for clinical low risk) |
Chemobenefit (≥21 for clinical low risk or ≥16 for clinical high risk) |
Total |
Non-chemobenefit (0–15 for clinical high risk or 0–20 for clinical low risk) |
Chemobenefit (≥21 for clinical low risk or ≥16 for clinical high risk) |
Total | |
| BCT score | Low risk (<4) | 245 (47.7%) | 105 (20.4%) | 350 (68.1%) | 217 (52.9%) | 82 (20.0%) | 299 (72.9%) | 28 (26.9%) | 23 (22.1%) | 51 (49.0%) |
| High risk (≥4) | 68 (13.2%) | 96 (18.7%) | 164 (31.9%) | 44 (10.7%) | 67 (16.3%) | 111 (27.1%) | 24 (23.1%) | 29 (27.9%) | 53 (51.0%) | |
| Total | 313 (60.9%) | 201 (39.1%) | 514 (100.0%) | 261 (63.7%) | 149 (36.3%) | 410 (100.0%) | 52 (50.0%) | 52 (50.0%) | 104 (100.0%) | |
BCT, Breast Cancer Test; RS, recurrence score; TAILORx, Trial Assigning Individualized Options for Treatment.
Clinical risk was determined using the modified Adjuvant! Online as reported in the MINDACT trial.